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Abstract
Background: Pneumonia is the major cause of mortality and morbidity in children worldwide. Procalcitonin (PCT) and C-
reactive protein (CRP) are used in developed countries to differentiate between viral and bacterial causes of pneumonia.
Validity of these markers needs to be further explored in Africa.
Methodology and Principal Findings: We assessed the utility of PCT and CRP to differentiate viral from invasive bacterial
pneumonia in children ,5 years hospitalized with clinical severe pneumonia (CSP) in rural Mozambique, a malaria-endemic
area with high HIV prevalence. Prognostic capacity of these markers was also evaluated. Out of 835 children with CSP, 87
fulfilled definition of viral pneumonia and 89 of invasive bacterial pneumonia. In absence of malaria parasites, levels of PCT
and CRP were lower in the viral group when compared to the invasive bacterial one (PCT: median=0.21 versus 8.31 ng/ml,
p,0.001; CRP: 18.3 vs. 185.35 mg/l, p,0.001). However, in presence of malaria parasites distribution between clinical
groups overlapped (PCT: median=23.1 vs. 21.75 ng/ml, p=0.825; CRP: median=96.8 vs. 217.4 mg/l, p=0.052). None of the
two markers could predict mortality.
Conclusions: Presence of malaria parasites should be taken into consideration, either for clinical or epidemiological
purposes, if using PCT or CRP to differentiate viral from invasive bacterial pneumonia in malaria-endemic areas.
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Introduction
Pneumonia is the major cause of morbidity and mortality in
children worldwide. More than 90% of the estimated 1.6 million
annual pneumonia deaths in children ,5 years occur in
developing countries [1] and are mainly due to bacteria [2].
However, viruses are isolated in 50–60% of in-hospital pneumonia
episodes [3–7] and clinical presentation between the two
pathogens is poorly specific. Furthermore, laboratory diagnosis
to determine viral or bacterial etiology lack sensitivity and their use
is limited in developing countries.
In rural Africa, pneumonia diagnosis is mainly based on
WHO’s Integrated Management of Childhood Illness (IMCI), a
set of highly sensitive clinical algorithms developed to guide
management of most common mortality causes in children. IMCI
has contributed to the reduction of pneumonia childhood
mortality [8,9]. Its algorithms are, however, unable to discriminate
between bacterial and non-bacterial causes of pneumonia while
only the formers require treatment with antibiotics. Any
improvement on clinical endpoints to differentiate bacterial
pneumonia with no requirement of laboratory facilities might
help management of treatment. The current pneumonia diagnosis
also has implications in determining the true burden of pneumonia
in epidemiological studies and in measuring the effects of
interventions such as vaccination against specific bacteria [10,11].
Biomarkers to differentiate viral from bacterial infections have
been evaluated mostly in the developed world to support clinical
diagnosis and to be applied as rapid diagnostic tests (RDT).
Despite disparity in results [12,13], procalcitonin (PCT) and C-
reactive protein (CRP) are used for etiological diagnosis in children
with pneumonia, assuming higher levels of both markers in
bacterial infections when compared to viral ones. Validity of these
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be assessed in the African continent. Plasmodium falciparum, highly
prevalent among children in most of Africa, increases levels of
CRP [14,15]. Epidemiological data from a pneumococcal vaccine
trial conducted in South Africa, a country with virtually no
malaria, suggested that PCT and CRP can contribute to increase
pneumonia endpoint specificity resulting in an increase of
measured efficacy [10]. However, improvement of specificity was
less marked in a similar study conducted in The Gambia, a
malaria-endemic country [11]. A recent study in Malawi shows
that PCT and CRP in presence of bacterial pneumonia/
meningitis were elevated in both HIV-uninfected and infected
children [16], but data on malaria in this study were poor. How
malaria parasitemia and other prevalent co-morbidities may alter
PCT and CRP levels in presence of pneumonia remains to be
explored.
In this study, we assessed the utility of PCT and CRP to
differentiate viral from invasive bacterial pneumonia in children in
Manhic ¸a, a rural malaria-endemic area of Mozambique with high
HIV prevalence. Prognostic capacity of these markers was also
evaluated.
Methods
Study area and population
This study was conducted by the Centro de Investigac ¸a ˜o em Sau ´de da
Manhic ¸a (CISM) at the Manhic ¸a District Hospital (MDH), the
referral health facility for Manhic ¸a District, a rural malaria-
endemic area of Southern Mozambique with subtropical climate
[17].
Since 1996, the CISM has been running continuous Demo-
graphic Surveillance System (DSS). The DSS covers 500 km
2 and
approximately 80000 inhabitants, 18% are children ,5 years.
Under-five mortality rate was 138.6/1000 in 2005 [18]. Each
child living within the DSS area is issued a unique permanent
identification number allowing tracking of demographic and
clinical data collected at the hospital.
Severe pneumonia accounted for 16% of admissions to MDH
and 11% of case-fatality rate among children ,2 years in 2004–
2006; 19% of these children presented clinical malaria [19].
Severe malnutrition prevalence in children ,5 years admitted to
MDH was 10% in 2001–2003 [20]. HIV prevalence among
pregnant woman attending to hospital antenatal clinic was 23.6%
in 2004 [21]. Antiretroviral therapy at the time of delivery has
been available in MDH since 2003. Mother-to-child transmission
rate was estimated to be 12.4% during that period. More than
25% of HIV-infected children died before 1 year [22].
Hospital surveillance and clinical management
The MDH is a 110 bed hospital with 36 paediatric beds. Since
1997, MDH and CISM have operated round-the-clock surveil-
lance of all paediatric visits [17]. Finger prick blood is obtained for
malaria determination and packed-cell volume (PCV) in children
with fever (axillary temperature $37.5uC) or history of fever in the
last 24 hours. Blood cultures are performed upon hospital
admission for all children ,2 years or older with axillary
temperature $39uC or other severity signs. Lumbar puncture is
performed in hospitalized children with suspicion of sepsis or
neurological impairment [23].
Patient’s selection and sample collection
This analysis is part of a larger study designed to describe
clinical and epidemiological characteristics of children ,5 years
admitted to the MDH with suspected clinical severe pneumonia
(CSP) between 20
th September 2006 and 19
th September 2007 [7]
(Bassat, Q. et al., unpublished). CSP was defined as cough and
difficult breathing with increased respiratory rate according to age
group and at least one of the following signs: indrawing, nasal
flaring, grunting or crackles. Written informed consent was
obtained from all participants parents or legal guardians involved
in the study. The study was approved by the Mozambican
National Bioethics Committee and the Institutional Review Board
of the Hospital Clı ´nic de Barcelona (HCB).
As part of the study protocol, blood sample was collected on
admission for full blood cell count and PCT/CRP determination.
Nasopharyngeal aspirate (NPA) was collected to detect respiratory
viruses. Blood culture and malaria determination were extended to
all children with CSP. Chest-x-rays were also performed. Children
residing in the DSS area were offered voluntary HIV counseling
and testing. Additional written informed consent and finger prick
blood were required.
According to definitions, children with CSP were classified in
two groups, viral and invasive bacterial pneumonia. Children who
presented clinical suspicion of Pneumocystis pneumonia (PCP) or,
according to parents/legal guardian, had received antibiotics
before admission were excluded from the analysis.
Asymptomatic healthy children ,5 years from the DSS area
were randomly selected to participate into this study as part of the
control group. After parental/legal guardian consent, blood was
collected for determination of malaria and PCT/CRP levels. No
other tests were performed to this group.
Study groups
Viral pneumonia was defined when a child presented on
admission with a normal chest x-ray or with abnormalities other
than alveolar consolidation or pleural effusion [24], ,15610
9/l
leukocytes in blood, a negative blood culture and at least one of the
following viruses isolated from NPA: respiratory syncytial virus
(RSV), influenza (Flu), parainfluenza (PIV), human metapneumo-
virus (hMPV) and adenovirus (ADV).
Invasive bacterial pneumonia was defined when a bacteria was
isolated from blood, excluding potential contaminants [Staphylo-
coccus epidermidis, Viridans group Streptococci and Bacillus spp. (non
anthracis)].
Control group was defined as healthy children from the
community with absence of fever, signs or symptoms of illness
and P. falciparum parasites.
Laboratory methods
P. falciparum parasites were detected by microscope observation
of thick and thin Giemsa-stained blood films [25]. PCV was
measured using microcentrifugue and a Hawksley hematocrit
reader card (Hawksley & Sons Ltd, UK). Blood cultures were
performed using an automated system (BACTECH 9050; Becton-
Dickinson, Franklin Lake, NJ, USA). Positive blood cultures were
examined following standard procedures [20,26].
To detect RSV, Flu, PIV, hMPV and ADV from NPA two
single polymerase chain reactions (PCR) and two multiplex PCRs
were performed [7].
HIV testing was done using two RDT: DetermineH (Abbott
Laboratories, North Chicago, IL, USA) and UnigoldH (Trinity
Biotech, Bray, Ireland). HIV-1 infection was confirmed using
antigen DNA-PCR Roche HIV-1 DNA testH (Roche Molecular
Systems, Branchburg, NJ, USA) for ,18 months positive
children and for those cases with discordant results from the two
RDT.
Plasma obtained from 1.5 ml of blood in EDTA (5 minutes,
1500 rpm) after full blood cell count was stored at -20uC until
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Sunyer. PCT quantification was performed using automated
immunoanalysis with LiaisonH (Diasorin, Saluggia, Italy) or Kryptor
CompactH (Brahms, Hennigsdorf, Germany). For CRP, immuno-
turbidimetric assay with ADVIA Chemistry CRP_2H (Siemens
Medical Solutions Diagnostics, Tarrytown, NY, USA) was used.
Limits of detection of these techniques were 0.04 ng/ml, 0.02 ng/
ml and 4 mg/l respectively.
Data management and statistical analysis
Data were double entered using Fox Pro version 2.6 (Microsoft
Corporation, Redmond, WA, USA) and analyzed using STATA
version 11 (Stata Corporation, College Station, TX, USA).
Discrepancies in data entry were resolved by referring to the
original forms.
Proportions were compared using Chi-square test. Distributions
of both markers were evaluated by mean of Kruskall-Wallis test.
Linear regression models were estimated to evaluate the difference
of PCT and CRP levels, adjusted by HIV, hematocrit, oxygen
saturation and malnutrition. P-value of 0.05 or lower was
considered significant.
Optimal cut-offs to determine viral (used as reference) and
invasive bacterial pneumonia were investigated using receiver
operating characteristic analyses.
Results
Study profile
A total of 835 children admitted to MDH during the study
period met study entry criteria, 190 (23%) fulfilled definition for
viral or invasive bacterial pneumonia. Both plasma and P.
falciparum determinations were available for 176 (93%) of these
children, 87 (49%) corresponding to the viral group and 89 (51%)
to the invasive bacterial one. 93 viruses were detected from the 87
children in the viral group (6 viral co-infections), being the most
prevalent viruses in decreasing order: ADV (n=33), RSV (n=18),
hMPV (n=16), Flu (n=15), PIV (n=11). 90 bacteria were
detected from the 89 children in the invasive bacterial group (1
bacterial co-infection), being the most prevalent bacteria in
decreasing order: Streptococcus pneumoniae (n=42), Haemophilus
influenzae type b (n=16), Staphylococcus aureus (n=7), Escherichia coli
(n=6), Salmonella spp (n=6), others (n=13). A total of 37 children
met criteria of the control group.
Overall, 11% (17/157) of the children in the clinical groups with
outcome data died in-hospital. All fatalities occurred in the
invasive bacterial group. Comparison of descriptive and clinical
features among groups is shown in Table 1.
Evaluation of causes attributable to pneumonia
PCT values comparing control, viral and invasive
bacterial groups. Median PCT concentration in the control
group was 0.05 ng/ml. Values in this group were lower compared
to clinical groups (n=37 versus n=166, p,0.001). In the viral
group median values were 0.21 ng/ml and 23.1 ng/ml in absence
and in presence of P. falciparum (n=62 and n=23, p,0.001). In
the invasive bacterial group median values corresponded to
8.31 ng/ml and 21.75 ng/ml in absence and in presence of P.
falciparum (n=74 and n=7, p=0.953). In absence of P. falciparum
(Figure 1A), PCT distribution between viral and invasive bacterial
groups was different (p,0.001) and presented low overlap of
values. In presence of P. falciparum (Figure 1B), PCT distribution
between clinical groups clearly overlapped (p=0.825).
CRP values comparing control, viral and invasive
bacterial groups. Median CRP concentration in control
group was 4 mg/l. Values in this group were lower compared to
clinical groups (n=33 versus n=169, p,0.001). In the viral group
median values were 18.3 mg/l and 96.8 mg/l in absence and in
presence of P. falciparum (n=59 and n=23, p,0.001). In the
invasive bacterial group median values corresponded to
185.4 mg/l and 217.4 mg/l in absence and in presence of P.
falciparum (n=80 and n=7, p=0.365). In absence of P. falciparum
(Figure 2A), distribution between viral and invasive bacterial
groups was different (p,0.001) and presented low overlap of
values. In presence of P. falciparum (Figure 2B), CRP distribution
between clinical groups overlapped (p=0.052).
Further analyses were performed in absence of P. falciparum due
to the observed effect of malaria parasites in PCT and CRP levels.
PCT and CRP intra clinical groups variability. PCT and
CRP distribution was compared within clinical groups according
Table 1. Descriptive and clinical features of children ,5 years
included in the viral, invasive bacterial and control groups.
Variables
Viral
pneumonia
(n=87)
Invasive
bacterial
pneumonia
(n=89)
Control
group
(n=37) p-value
Age
,1 month 3 (3) 6 (7) 0 (0)
1-,12 months 32 (37) 40 (45) 13 (35) 0.223
1-,5 years 52 (60) 43 (48) 24 (65)
Sex
Male 57 (66) 55 (62) 24 (65) 0.868
Female 30 (34) 34 (38) 13 (35)
Malnutrition*
(n=155)
No 71 (83) 47 (68) NA{ 0.036
Yes 15 (17) 22 (32) NA
Hematocrit (n=175)
$33% 47 (54) 31 (35) NA
15 -,33% 40 (46) 56 (64) NA 0.031
,15% 0 (0) 1 (1) NA
P. falciparum
No 64 (74) 82 (92) NA 0.001
Yes 23 (26) 7 (8) NA
HIV (n=110)
No 58 (95) 23 (47) NA ,0.001
Yes 3 (5) 26 (53) NA
Mortality (n=157)
No 85 (100) 55 (76) NA ,0.001
Yes 0 (0) 17 (24) NA
Oxygen saturation{
(n=174)
$94% 53 (61) 44(50) NA
90 - ,94% 16 (18) 19 (22) NA 0.377
,90% 18(21) 24 (28) NA
NOTE. Data are n (%) of patients, unless otherwise indicated.
*Weight to age z-score ,3 SDs from U.S. reference population.
{NA: Not applying. When data from the control group does not apply, the
p-value is obtained from the comparison of the two clinical groups.
{Measured with pulsioximetry.
doi:10.1371/journal.pone.0013226.t001
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bacterial group). In absence of P. falciparum no differences were
found in PCT and CRP distribution within viruses (p=0.482 and
p=0.649) (Figure S1, online). The same occurred in PCT and
CRP distribution within invasive bacteria (p=0.145 and
p=0.513) (Figure S2, online).
Adjusted analysis of PCT and CRP levels. As shown in
Table 2, when adjusting PCT levels with clinical variables in
absence of malaria parasites only clinical group (viral versus
invasive bacterial) was significantly associated to PCT levels
(p,0.001). On the contrary, CRP levels were associated with
clinical group and hematocrit (p,0.001 and p=0.036). None of
the both markers was associated to HIV status (p=0.854 and
p=0.331 respectively).
PCT and CRP diagnostic accuracy. In absence of P.
falciparum, the area under the curve (AUC) in predicting clinical
group was 0.9 for PCT and 0.87 for CRP (n=129, p=0.32). PCT
and CRP cut-offs were maximized respectively at 0.72 ng/ml
(sensitivity 94.6%, specificity 74.2%) and 20.9 mg/l (sensitivity
95%, specificity 54.2%). Combination of both markers did not
improve diagnostic profile (data not shown).
Evaluation of pneumonia prognosis
In absence of P. falciparum, PCT distribution between survivors
and fatalities was different (n=107 and n=12, p=0.018).
However, an important overlap of values was observed between
the two groups (Figure 3A). Median values were 1.08 ng/ml and
19.75 ng/ml respectively. For CRP, distribution between out-
comes in absence of P. falciparum was different (n=108 and n=15,
p=0.038). However, an important overlap of values was observed
between the two groups (Figure 3B). Median values were
60.95 mg/l and 161.3 mg/l. The AUC for PCT and CRP in
predicting death was poor (0.68 and 0.64, n=113, p=0.5). When
considering only the invasive bacterial group in absence of P.
falciparum, there was also an important overlap of PCT and CRP
values between survivors and fatalities (data not shown).
Discussion
We have assessed the usefulness of PCT and CRP to
differentiate viral from invasive bacterial pneumonia in rural
Africa, where malaria, HIV and other co-morbidities are
common. Our main finding is that PCT and CRP can not
differentiate between these two clinical groups among hospitalized
children with malaria parasites. However, both markers can
differentiate these two groups in absence of malaria parasites and
independently of their HIV status. None of the two markers could
predict mortality.
According to our results PCT and CRP have similar
distribution among study clinical groups in presence of P.
Figure 2. Distribution of C-reactive protein (CRP) concentra-
tions in the viral and the invasive bacterial group.
doi:10.1371/journal.pone.0013226.g002
Figure 1. Distribution of procalcitonin (PCT) concentrations in
the viral and the invasive bacterial group.
doi:10.1371/journal.pone.0013226.g001
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showed no significant differences in PCT and CRP levels between
children with and without malaria infection [16]. An explanation
could be that 74% (280/377) of the cases with signs of
pneumonia/meningitis presented with serious bacterial infection
and only 4% (13/360) of cases were positive for P. falciparum. We
do not know the clinical group of these 13 cases. Along with our
findings, studies conducted in The Gambia and Tanzania
observed that malaria infection increased levels of CRP [14,15].
Although our results show restrictions on the use of PCT and CRP
in a malaria-endemic context, presence of P. falciparum can rapidly
be assessed with a RDT. In African malaria-endemic countries
efforts are being done to establish malaria parasitological diagnosis
as routine practice [27].
Strategies to reduce pneumonia burden of disease and severity
include prevention through early diagnosis and selection of
appropriate treatment. In a context where pneumonia plays an
important role in high in-hospital mortality and where diagnostic
facilities are poor, all children meeting WHO criteria for
CSP should be treated empirically with parenteral antibiotics.
Our study suggests that in in-hospital children without WHO
criteria for parenteral antibiotics, elevated levels of PCT or CRP
in absence of malaria parasites could indicate the need of
antibiotics. Additionally, in absence of malaria parasites elevated
levels of PCT and CRP could warn of invasive bacterial
pneumonia at peripheral health posts and outpatient departments.
This might respectively facilitate transfer to hospital and
admission, as well as rationalization and prioritization of
antibiotics administration.
Standardized definitions of pneumonia in epidemiological
studies are still a challenge and measurement of disease burden
and efficacy in vaccine trials is necessary using proxy measures.
WHO and CDC jointly developed a generic protocol to measure
burden of pneumonia using standardized definitions based on
radiological interpretation [24]. Although these definitions have
been used to determine pneumococcal and Haemophilus influenzae
pneumonia in epidemiological and intervention studies [28–32];
their applicability in rural settings of developing countries is
limited, even in research studies, due to the scarcity of radio-
logical facilities. Taking this into account, researchers from South
Africa aimed to improve definitions that are easier to apply in the
African context. Such definitions included measurement of PCT
and/or CRP on admission of children presenting with clinical
pneumonia [10]. As we have shown, improvement of epidemio-
logical definitions with PCT and/or CRP may be limited in
malaria-endemic countries, as malaria parasites increase levels of
both markers independently of the pathogen responsible of
pneumonia. This may help explain why values of specificity found
in The Gambia [11] were lower than those detected in South
Africa [10] when using similar pneumonia definitions, as only the
former is a malaria-endemic country. To our understanding,
specificity of the definition will be affected by malaria endemicity
and seasonality of the study area, but this needs to be further
explored.
To determine prognostic markers is another daily challenge for
clinicians in resource-limited settings. We also evaluated PCT and
CRP as predictors of mortality among clinical groups without P.
falciparum. Although the study was underpowered for this outcome,
no trend was observed. Similarly, PCT and CRP did not
demonstrate any value in predicting death among Malawian
children with signs of pneumonia or meningitis [16].
The major limitation of this study is related to the definitions of
the clinical groups. On one hand, we expect some miss-
classifications in the viral group due to undetectable incipient
bacterial co-infection [33]. If so, real differences would have been
wider than currently observed. Most important, invasive bacterial
Table 2. Adjusted analysis of markers levels.
Variables PCT (n=82) CRP (n=81)
Proportional
difference 95% CI p-value
Proportional
difference 95% CI p-value
Group
Viral 1 1
Invasive bacterial 33.68 10.61–107 ,0.001 7.86 3.7–16.69 ,0.001
HIV
No 1 1
Yes 0.88 0.24–3.31 0.854 0.66 0.28–1.54 0.331
Hematocrit
$33% 1 1
15 -,33% 1.28 0.46–3.59 0.631 2.05 1.05–3.99 0.036
,15% 0.82 0.01–67.85 0.927 1.26 0.07–21.32 0.873
Oxygen saturation
$94% 1 1
90 - ,94% 1.51 0.48–4.78 0.475 1.26 0.6–2.68 0.537
,90% 1.13 0.33–3.96 0.842 1.7 0.76–3.8 0.193
Malnutrition
No 1 1
Yes 0.77 0.26–2.24 0.622 0.94 0.47–1.92 0.88
doi:10.1371/journal.pone.0013226.t002
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to bacteria. Overall, only 23% of in-hospital children with CSP
fulfilled viral or invasive bacterial pneumonia definitions. None of
these limitations invalidated our conclusions. However, our results
cannot asses the need of antibiotic in non bacteremic cases of
pneumonia associated to bacteria. Additionally, how PCT and
CRP levels are modified by other prevalent causes of pneumonia
in an area with high HIV-prevalence, such as PCP, should be
assessed in future studies.
In conclusion, this study provides evidence of the potential
utility of PCT and CRP to differentiate viral from invasive
bacterial pneumonia in children free of P. falciparum in areas
with high prevalence of HIV infection. How P. falciparum
parasites increase PCT and CRP levels independently of the
pathogen associated to pneumonia should be considered in the
application of these markers for clinical and/or epidemiological
purposes.
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